tetano
Editor, Senior Moderator
Dig Dis Sci
. 2021 Feb 24.
doi: 10.1007/s10620-021-06872-z. Online ahead of print.
Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis
Chenyu Sun[SUP] 1 [/SUP], Yue Chen[SUP] 2 [/SUP], Lei Hu[SUP] 2 [/SUP], Yile Wu[SUP] 3 4 [/SUP], Mingming Liang[SUP] 3 4 [/SUP], Mubashir Ayaz Ahmed[SUP] 5 [/SUP], Chandur Bhan[SUP] 5 [/SUP], Zhichun Guo[SUP] 6 [/SUP], Hongru Yang[SUP] 6 [/SUP], Yijing Zuo[SUP] 6 [/SUP], Yue Yan[SUP] 6 [/SUP], Qin Zhou[SUP] 7 [/SUP]
Affiliations
Abstract
Background: Famotidine was reported to potentially provide benefits to Coronavirus Disease 2019 (COVID-19) patients. However, it remains controversial whether it is effective in treating COVID-19.
Aims: This study aimed to explore whether famotidine use is associated with reduced risk of the severity, death, and intubation for COVID-19 patients.
Methods: This study was registered on International Prospective Register of Systematic Reviews (PROSPERO) (ID: CRD42020213536). A comprehensive search was performed to identify relevant studies up to October 2020. I-squared statistic and Q-test were utilized to assess the heterogeneity. Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated through the random effects or fixed effects model according to the heterogeneity. Subgroup analyses, sensitivity analysis, and publication bias assessment were also conducted.
Results: Five studies including 36,635 subjects were included. We found that famotidine use was associated with a statistically non-significant reduced risk of progression to severe disease, death, and intubation for Coronavirus Disease 2019 (COVID-19) patients (pooled RR was 0.82, 95% CI = 0.52-1.30, P = 0.40).
Conclusion: Famotidine has no significant protective effect in reducing the risk of developing serious illness, death, and intubation for COVID-19 patients. More original studies are needed to further clarify whether it is associated with reduced risk of the severity, death, and intubation for COVID-19 patients.
Keywords: COVID-19; Famotidine; Meta-analysis.
. 2021 Feb 24.
doi: 10.1007/s10620-021-06872-z. Online ahead of print.
Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis
Chenyu Sun[SUP] 1 [/SUP], Yue Chen[SUP] 2 [/SUP], Lei Hu[SUP] 2 [/SUP], Yile Wu[SUP] 3 4 [/SUP], Mingming Liang[SUP] 3 4 [/SUP], Mubashir Ayaz Ahmed[SUP] 5 [/SUP], Chandur Bhan[SUP] 5 [/SUP], Zhichun Guo[SUP] 6 [/SUP], Hongru Yang[SUP] 6 [/SUP], Yijing Zuo[SUP] 6 [/SUP], Yue Yan[SUP] 6 [/SUP], Qin Zhou[SUP] 7 [/SUP]
Affiliations
- PMID: 33625613
- DOI: 10.1007/s10620-021-06872-z
Abstract
Background: Famotidine was reported to potentially provide benefits to Coronavirus Disease 2019 (COVID-19) patients. However, it remains controversial whether it is effective in treating COVID-19.
Aims: This study aimed to explore whether famotidine use is associated with reduced risk of the severity, death, and intubation for COVID-19 patients.
Methods: This study was registered on International Prospective Register of Systematic Reviews (PROSPERO) (ID: CRD42020213536). A comprehensive search was performed to identify relevant studies up to October 2020. I-squared statistic and Q-test were utilized to assess the heterogeneity. Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated through the random effects or fixed effects model according to the heterogeneity. Subgroup analyses, sensitivity analysis, and publication bias assessment were also conducted.
Results: Five studies including 36,635 subjects were included. We found that famotidine use was associated with a statistically non-significant reduced risk of progression to severe disease, death, and intubation for Coronavirus Disease 2019 (COVID-19) patients (pooled RR was 0.82, 95% CI = 0.52-1.30, P = 0.40).
Conclusion: Famotidine has no significant protective effect in reducing the risk of developing serious illness, death, and intubation for COVID-19 patients. More original studies are needed to further clarify whether it is associated with reduced risk of the severity, death, and intubation for COVID-19 patients.
Keywords: COVID-19; Famotidine; Meta-analysis.